This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Trissel, L. A. Articles by Mirtallo, J. M. Search for Related Content PubMed PubMed Citation Articles by Trissel, L. A. Articles by Mirtallo, J. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMIKACIN GLUCOSE SODIUM CHLORIDE Social Bookmarking                         What's this?

Compatibility of Medications With 3-in-1 Parenteral Nutrition Admixtures

Clinical Pharmaceutics Research Program, University of Texas, M.D. Anderson Cancer Center, Houston, Texas

Doward L. Gilbert

Texas Southern University, Houston, Texas

Juan F. Martinez

Pharmaceutical Analysis Laboratory, Division of Pharmacy, University of Texas, M.D. Anderson Cancer Center, Houston, Texas

Mary B. Baker, PharmD

Hospital Products Division, Abbott Laboratories, Abbott Park, Illinois

William V. Walter, PhD

Pharmaceutical Development, McGaw, Inc, Irvine, California, Walter Pharmaceutical Consultants, Inc, Huntington Beach, California

Jay M. Mirtallo, MS, FASHP

Pharmacy Department, Ohio State University Medical Center, Columbus

Background: The absence of drug compatibility information with 3-in-1 parenteral nutrition admixtures has been problematic. The purpose of this project was to evaluate the physical compatibility of 106 selected drugs during simulated Y-site injection into nine different 3-in-1 parenteral nutrition admixture formulations. Methods: Four-milliliter samples of each of the representative 3-in-1 parenteral nutrition admixture formulations were combined in a 1:1 ratio with 4-mL samples of each of 106 drugs, including supportive care drugs, anti-infectives, and antineoplastic drugs. Six replicate samples of each combination were prepared. Two samples were evaluated initially after mixing, two more after 1 hour, and the last two after 4 hours at 23°C. At each test interval, the samples were subjected to centrifugation, causing the fat to rise to the top. The top fat layer and most of the aqueous phase were removed, and the remaining liquid was diluted with about 7 mL of particle-free, high-performance liquid chromatography—grade water to facilitate observation of any particulates that might have formed. Visual examinations were performed in normal diffuse fluorescent laboratory light and under high-intensity, monodirectional light. Results: Most of the drugs tested were physically compatible with the 3-in-1 parenteral nutrition admixtures for 4 hours at 23°C. However, 23 drugs exhibited various incompatibilities with one or more of the parenteral nutrition admixtures. Six drugs resulted in the formation of precipitate with some or all of the admixtures. Seventeen drugs caused disruption of the emulsion, usually with oiling out. Conclusions: Most of the test drugs were physically compatible with the nine representative 3-in-1 parenteral nutrition admixtures. However, the 23 drugs that resulted in incompatibilities should not be administered simultaneously with the incompatible parenteral nutrition admixtures via a Y injection site. (Journal of Parenteral and Enteral Nutrition 23:67-74, 1999)

Journal of Parenteral and Enteral Nutrition, Vol. 23, No. 2, 67-74 (1999)
DOI: 10.1177/014860719902300267


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Chan, A. Bishop, T. C. Kupiec, L. A. Trissel, D. Gole, I. M. Jimidar, and H. Vermeersch Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration Am. J. Health Syst. Pharm., August 15, 2008; 65(16): 1545 - 1551. [Abstract] [Full Text] [PDF]

				M. K. Brammer, P. Chan, K. Heatherly, C. Trusley, T. C. Kupiec, L. A. Trissel, P. A. Psathas, T. Gilmor, and D. Schaufelberger Compatibility of doripenem with other drugs during simulated Y-site administration Am. J. Health Syst. Pharm., July 1, 2008; 65(13): 1261 - 1265. [Abstract] [Full Text] [PDF]

				American Society for Parenteral and Enteral Nutrit Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients JPEN J Parenter Enteral Nutr, January 1, 2002; 26(1_suppl): 1SA - 138SA. [PDF]